Myriad Genetics (MYGN)

Q4 2011 Earnings Call

August 09, 2011 4:30 pm ET


Peter Meldrum - Chief Executive Officer, President and Director

Rebecca Chambers -

James Evans - Chief Financial Officer, Principal Accounting Officer and Treasurer

Mark Capone - President of Myriad Genetic Laboratories Inc


Scott Gleason - Stephens Inc.

Dane Leone - Macquarie Research

Charles Duncan - JMP Securities LLC

Tycho Peterson - JP Morgan Chase & Co

Michael Yee - RBC Capital Markets, LLC

Doug Schenkel - Cowen and Company, LLC

Unknown Analyst -

Jon Wood - Jefferies & Company, Inc.



Ladies and gentlemen, thank you for standing by, and welcome to the Myriad Genetics 2011 Financial Earnings Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded, Tuesday, August 9, 2011. I would now like to turn the conference over to Rebecca Chambers, Director of Investor Relations. Please go ahead, ma'am.

Rebecca Chambers

Thank you, Lindsay. Good afternoon, everyone, and welcome to the Myriad Genetics Fourth Quarter and Fiscal Year 2011 Earnings Call. During the call, we will review the financial results we've released today and detail the strategic directives, which will guide the company on fiscal 2012, after which we will host a question-and-answer session. If you had not had a chance to review the earnings release, it can be found in the Investor Relations section of our website at

Presenting today will be Pete Meldrum, President and Chief Executive Officer; Mark Capone, President, Myriad Genetic Laboratories; and Jim Evans, Chief Financial Officer. This call can be heard live via webcast along with the slide presentation at The call is being recorded and will be archived along with the presentation in the Investors section of our website.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments